Paclitaxel for ovarian cancer.
Paclitaxel (Taxol-Bristol-Myers Squibb) is the first of a new group of cytotoxic drugs, the taxanes. It is licensed for the treatment of patients with metastatic ovarian carcinoma "where standard, platinum-containing, therapy has failed". What is its place in treatment?
D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000556:secondary; D017239:Paclitaxel / Q000191:economics / Q000627:therapeutic use*
D017239:Paclitaxel